View Document Preview and Link
Open Document File Size: 1,26 MB Share Result on Facebook
Company U.S.A. U. / Sentinel / FDA’s / Drug Evaluation and Research / / Country United States / / Event FDA Phase / Business Partnership / / Facility bridge Initiative / / IndustryTerm biological products / scientific tools / approval individual healthcare facilities / similar products / discoveries network / clinical development innovative technologies / biopharmaceutical industry / imaging / healthcare databases / therapies for rare diseases / treatment of HIV / cord blood product / pharmaceutical innovation / blood product / biopharmaceutical innovation / drug cord-blood products / / MedicalCondition each rare disease / rare diseases / HIV / arterial hypertension / transfusion-dependent anemia / pulmonary arterial hypertension / Macular Degeneration / common skin cancer / advanced basal cell carcinoma / Cystic Fibrosis / Blood Disorders / orphan diseases / blindness / serious diseases / Alzheimer’s disease / Cancer / disease / Three diseases / autism / bone marrow disease myelofibrosis / critical Alzheimer’s disease / diabetes / Gaucher Disease / kidney failure / Fabry disease / diseases / AIDS / HIV/AIDS / epilepsy / Meningitis / / MedicalTreatment chemotherapy / drug therapies / / Organization National Institute of Health / Food and Drug Administration / /ReportsManualsForms/Reports/ucm276385.htm U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES U.S. FOOD AND DRUG ADMINISTRATION FY / Innovation Act / Medicines Agency / FDA / Center for Biologics Evaluation and Research / Drug Administration / / Position Efficiently EXECUTIVE / Executive / / Product Sentinel Initiative / Voraxaze / FY / U.S / FDA / / PublishedMedium the Sentinel / / Region U.S. U.S. / / Technology chemotherapy / drug development / / URL http / SocialTag